Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.18 HKD | -2.48% | -7.81% | -19.18% |
Apr. 03 | Ascletis Discontinues Trials of FXR Agonist for Biliary Cholangitis, NASH and Hepatitis B Virus | MT |
Apr. 03 | Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42 | CI |
ETFs positioned on Ascletis Pharma Inc.
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.78% | 4 M€ | -27.92% | ||
0.00% | 34 M€ | +3.86% | - |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.18% | 157M | |
-2.21% | 89.87B | |
-3.95% | 37.57B | |
+63.05% | 26.47B | |
-22.14% | 14.25B | |
-7.96% | 12.99B | |
-9.33% | 11.93B | |
-46.33% | 10.84B | |
+5.77% | 9.11B | |
-19.53% | 7.32B |
- Stock Market
- Equities
- 1672 Stock
- Funds and ETFs Ascletis Pharma Inc.